HK1250480A1 - 用於治疗hbv感染的组合物和方法 - Google Patents

用於治疗hbv感染的组合物和方法 Download PDF

Info

Publication number
HK1250480A1
HK1250480A1 HK18109890.2A HK18109890A HK1250480A1 HK 1250480 A1 HK1250480 A1 HK 1250480A1 HK 18109890 A HK18109890 A HK 18109890A HK 1250480 A1 HK1250480 A1 HK 1250480A1
Authority
HK
Hong Kong
Prior art keywords
treatment
methods
compositions
hbv infection
infection
Prior art date
Application number
HK18109890.2A
Other languages
English (en)
Chinese (zh)
Inventor
Radhakrishnan P. Iyer
Original Assignee
Spring Bank Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spring Bank Pharmaceuticals, Inc. filed Critical Spring Bank Pharmaceuticals, Inc.
Publication of HK1250480A1 publication Critical patent/HK1250480A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
HK18109890.2A 2015-04-07 2016-04-07 用於治疗hbv感染的组合物和方法 HK1250480A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562144300P 2015-04-07 2015-04-07
US201562144300P 2015-04-07
US201562220406P 2015-09-18 2015-09-18
US201562220406P 2015-09-18
US201662279382P 2016-01-15 2016-01-15
US201662279382P 2016-01-15
PCT/US2016/026498 WO2016164619A2 (en) 2015-04-07 2016-04-07 Compositions and methods for the treatment of hbv infection

Publications (1)

Publication Number Publication Date
HK1250480A1 true HK1250480A1 (zh) 2018-12-21

Family

ID=57072854

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18109890.2A HK1250480A1 (zh) 2015-04-07 2016-04-07 用於治疗hbv感染的组合物和方法

Country Status (10)

Country Link
US (1) US20180110796A1 (enExample)
EP (1) EP3280422A4 (enExample)
JP (1) JP2018512428A (enExample)
KR (1) KR20170132327A (enExample)
CN (1) CN107635566A (enExample)
AU (1) AU2016244828A1 (enExample)
CA (1) CA2982125A1 (enExample)
HK (1) HK1250480A1 (enExample)
TW (1) TW201709912A (enExample)
WO (1) WO2016164619A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190290673A1 (en) * 2016-10-24 2019-09-26 Spring Bank Pharmaceuticals, Inc. Compositions and methods for the treatment of hbv infection
KR101899773B1 (ko) * 2017-03-07 2018-09-18 일동제약(주) 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법
WO2020040327A1 (ko) * 2018-08-23 2020-02-27 광주과학기술원 시클로피록스의 hbv 코어조립 저해 용도
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CA3155068A1 (en) * 2019-09-29 2021-04-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Drug combination containing tlr7 agonist
EP4037706A4 (en) * 2019-10-02 2023-09-13 University of Washington Compositions and methods for treatment of hepatitis b virus infection
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
KR102292147B1 (ko) * 2020-11-18 2021-08-23 주식회사 차백신연구소 경구용 항바이러스제 및 리포펩타이드와 폴리(i:c) 아쥬반트를 포함한 치료백신을 유효성분으로 포함하는 만성 b형 간염의 예방 또는 치료용 약제학적 조성물, 약제학적 병용제제, 병용제 키트
WO2022115765A1 (en) * 2020-11-30 2022-06-02 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis e virus infection with interferon lambda

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2913889A (en) * 1987-11-16 1989-06-14 Fox Chase Cancer Center Determination of anti-pol as an early marker of viral hepatitis infection
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
CN1268345C (zh) * 2000-03-29 2006-08-09 乔治敦大学 治疗丁型肝炎病毒感染的核苷化合物
US7202354B2 (en) * 2001-03-30 2007-04-10 Abbott Laboratories Hepatitis B virus surface antigen mutant and methods of detection thereof
CA2529997A1 (en) * 2003-06-20 2004-12-29 Dade Behring Marburg Gmbh Novel surface protein (hbsag) variant of hepatitis b virus
CN101278938A (zh) * 2008-03-20 2008-10-08 黑龙江加州国际投资咨询有限公司 泰诺福韦酯和恩替卡韦的复方制剂及其抗乙肝病毒的应用
EP2271351A4 (en) * 2008-04-03 2016-08-31 Spring Bank Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
CN103298475A (zh) * 2010-08-30 2013-09-11 斯普林银行医药公司 作为治疗剂的寡核苷酸类似物的设计

Also Published As

Publication number Publication date
AU2016244828A1 (en) 2017-10-26
EP3280422A2 (en) 2018-02-14
WO2016164619A3 (en) 2016-12-08
WO2016164619A2 (en) 2016-10-13
CN107635566A (zh) 2018-01-26
EP3280422A4 (en) 2018-12-05
JP2018512428A (ja) 2018-05-17
US20180110796A1 (en) 2018-04-26
KR20170132327A (ko) 2017-12-01
TW201709912A (zh) 2017-03-16
CA2982125A1 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
HK1250480A1 (zh) 用於治疗hbv感染的组合物和方法
ZA201708236B (en) Methods and compositions for rna-guided treatment of hiv infection
IL258697A (en) Methods related to crispr/cas and compositions for the treatment of viral hepatitis b
EP3139954A4 (en) Methods and compositions for treating hepatitis b virus infections
IL245436A0 (en) New dihydroquinolizinones for the treatment and prevention of hepatitis b virus infection
PH12016501379A1 (en) Azepane derivatives and methods of treating hepatitis b infections
IL246449A0 (en) 6-compressed new heteroaryldihydropyrimidines for the treatment and prevention of hepatitis b virus infection
EP3331571A4 (en) COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS
EP3325097A4 (en) COMPOSITIONS AND AGENTS AGAINST HEPATITIS B VIRUSES AND USES THEREOF
MX383929B (es) Derivados y métodos de tratamiento de las infecciones por hepatitis b.
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
EP3512524A4 (en) METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS
IL249660B (en) Methods for treating hepatitis b virus and hepatitis d virus infections
EP3137078A4 (en) Treatment of hepatitis delta virus infection
EP3250553A4 (en) Compositions and methods for inhibiting viral infection
EP3634431A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS OF TREATMENT FOR HEPATITIS B
EP3226973A4 (en) Treatment of hepatitis delta virus infection
HK1255221A1 (zh) 使用卡多曲组合物进行治疗的方法
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
HK40118570A (zh) 治疗丁型肝炎病毒感染
HK40106696A (zh) 治疗乙型肝炎感染的方法
PL3810625T3 (pl) Sposoby i kompozycje do leczenia zakażenia wirusem zapalenia wątroby typu b
HK1259769A1 (en) Crispr/cas-related methods and compositions for treating hepatitis b virus
HK40016498A (en) Therapeutic compositions and methods for treating hepatitis b